Saul Malozowski, M.D., Ph.D., M.B.A.
Responsibilities & Activities
In my position as program director for the Endocrinology and Physiology Program, I coordinate scientific portfolios for bone research, neuroendocrinology, clinical endocrinology, and HIV/AIDS-associated metabolic and endocrine dysfunction. The bone program encompasses basic and clinical research on the hormonal regulation of bone and mineral metabolism in health and disease, endocrine aspects of disorders affecting bone, all facets of parathyroid development and disorders, the effects of systemic or local-acting hormones and their receptors on bone metabolism, bone-active cytokines, studies of calcium-related processes, basic and clinical studies of vitamin D, and studies addressing the impact of metabolic derangements in Type 1 and Type 2 diabetes mellitus on the skeleton.
My other research interests lie within studies surrounding neuroendocrinology that examine a range of topics, including the physiological response to stress through the hypothalamic-pituitary-adrenal axis, neuropeptides and their signaling pathways, gene regulation in the hypothalamus and pituitary gland, diseases of the pituitary and other endocrine glands, hormone receptors and actions on target tissues, and neuroendocrine-immune interactions.
My work for the Division of Diabetes, Endocrinology, and Metabolic Diseases also includes evaluation of human subject protection for all clinical research. I am also a member of the Trans NIH research group that addresses various topics on bone health. In addition, I am the program officer of The Vitamin D and Type 2 Diabetes Study (D2d study), a randomized multicenter placebo-controlled study assessing the safety and efficacy of vitamin D to prevent or delay the development of type 2 diabetes in subjects at risk. I am the scientific officer of The Vitamin D and Type 2 Diabetes Study (D2d study), a randomized multicenter placebo-controlled study that assessed the safety and efficacy of vitamin D to prevent or delay the development of type 2 diabetes in subjects at risk.
Finally, I am the program officer of the TODAY2 study that tracks the progression of Type 2 diabetes and related comorbidities and complications in the TODAY cohort as this cohort transitions to young adulthood.
Clinical Research in Type 2 Diabetes
Progression and treatment of type 2 diabetes in children and adults.
Diabetes & Metabolism HIV/AIDS
Studies on the metabolic complications of HIV infection and treatment, including endocrine and body composition abnormalities.
Endocrinology & Hormone Signaling
Endocrinology, neuroendocrinology, hormone signaling, nutrient sensing, the Hypothalamic-Pituitary- Axis, and bone metabolism.
Obesity, Pregnancy, & the Intrauterine Environment
Impact of metabolic dysfunction on the intrauterine environment and subsequent metabolic health of mother and offspring.
Committees & Working Groups
- Trans-HHS Bone Health Initiatives Committee, Member
- Trans-NIH Endocrine Working Group, Member
- Vitamin D for Bone Working Group, NIDDK Representative
Senior Advisor for Clinical Trials and Diabetes Translation, DEM, NIDDK, NIH, 2001-2005
Medical Team Leader, Division of Endocrine and Metabolic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 1998-2001
Visiting Fellow, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, 1983-1986
Chief Resident, Pediatric Endocrinology, Children's General Hospital, Dr. Ricardo Gutierrez, Buenos Aires, 1982-1983
Fellow in Pediatric Endocrinology, Children's General Hospital, Dr. Ricardo Gutierrez, Buenos Aires, 1980-1982
Pediatric Resident, Children's General Hospital, Dr. Ricardo Gutierrez, Buenos Aires, 1978-1980
M.B.A., The George Washington University School of Business and Public Management, 1996-1998
Ph.D., University of Buenos Aires School of Medicine, Argentina, 1990
M.D., University of Buenos Aires School of Medicine, Argentina, 1976